RS64388B1 - Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma - Google Patents
Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfomaInfo
- Publication number
- RS64388B1 RS64388B1 RS20230598A RSP20230598A RS64388B1 RS 64388 B1 RS64388 B1 RS 64388B1 RS 20230598 A RS20230598 A RS 20230598A RS P20230598 A RSP20230598 A RS P20230598A RS 64388 B1 RS64388 B1 RS 64388B1
- Authority
- RS
- Serbia
- Prior art keywords
- nivolumab
- blockade
- lymphoma
- refractory hodgkin
- hodgkin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344880P | 2016-06-02 | 2016-06-02 | |
PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
EP17730627.1A EP3463457B1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
RS64388B1 true RS64388B1 (sr) | 2023-08-31 |
Family
ID=59067911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20230598A RS64388B1 (sr) | 2016-06-02 | 2017-06-01 | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma |
Country Status (17)
Country | Link |
---|---|
US (2) | US11083790B2 (sr) |
EP (2) | EP4248990A3 (sr) |
JP (3) | JP7175198B2 (sr) |
KR (2) | KR20190015377A (sr) |
CN (1) | CN109475633A (sr) |
DK (1) | DK3463457T3 (sr) |
ES (1) | ES2954139T3 (sr) |
FI (1) | FI3463457T3 (sr) |
HR (1) | HRP20230864T1 (sr) |
HU (1) | HUE062398T2 (sr) |
LT (1) | LT3463457T (sr) |
PL (1) | PL3463457T3 (sr) |
PT (1) | PT3463457T (sr) |
RS (1) | RS64388B1 (sr) |
SI (1) | SI3463457T1 (sr) |
SM (1) | SMT202300290T1 (sr) |
WO (1) | WO2017210453A1 (sr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
PL3334763T3 (pl) | 2015-08-11 | 2024-12-02 | WuXi Biologics Ireland Limited | Nowe przeciwciała anty-pd-1 |
RS64388B1 (sr) | 2016-06-02 | 2023-08-31 | Bristol Myers Squibb Co | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma |
CN109476752A (zh) | 2016-06-02 | 2019-03-15 | 百时美施贵宝公司 | 抗-pd-1抗体与抗-cd30抗体的组合在淋巴瘤治疗中的用途 |
CA3084370A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
US20210047409A1 (en) * | 2018-02-13 | 2021-02-18 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
EP3946625A1 (en) * | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
EP2439272A3 (en) | 2005-05-09 | 2013-07-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
CA2734908A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
MX342591B (es) | 2008-12-09 | 2016-10-05 | Genentech Inc * | Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t. |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
EP2504364B1 (en) | 2009-11-24 | 2017-08-09 | Medimmune Limited | Targeted binding agents against b7-h1 |
ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗pd−l1抗体及びその使用 |
EP3309175A1 (en) | 2012-05-15 | 2018-04-18 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US9315567B2 (en) * | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
JP6563906B2 (ja) | 2013-05-31 | 2019-08-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−1に結合する抗原結合蛋白質 |
ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
JP6502959B2 (ja) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | Pd−1抗体、その抗原結合性断片及びそれらの医学的使用 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法 |
RS64388B1 (sr) | 2016-06-02 | 2023-08-31 | Bristol Myers Squibb Co | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma |
-
2017
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko active Application Filing
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
- 2017-06-01 SM SM20230290T patent/SMT202300290T1/it unknown
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en unknown
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Application Discontinuation
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en not_active Abandoned
-
2022
- 2022-11-08 JP JP2022178836A patent/JP7568698B2/ja active Active
-
2024
- 2024-10-03 JP JP2024174007A patent/JP2025020119A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109475633A (zh) | 2019-03-15 |
US20220025049A1 (en) | 2022-01-27 |
JP2025020119A (ja) | 2025-02-12 |
EP3463457A1 (en) | 2019-04-10 |
JP2023025012A (ja) | 2023-02-21 |
ES2954139T3 (es) | 2023-11-20 |
DK3463457T3 (da) | 2023-10-02 |
JP7568698B2 (ja) | 2024-10-16 |
SMT202300290T1 (it) | 2023-11-13 |
US20190290757A1 (en) | 2019-09-26 |
EP4248990A2 (en) | 2023-09-27 |
WO2017210453A1 (en) | 2017-12-07 |
KR20230038318A (ko) | 2023-03-17 |
KR20190015377A (ko) | 2019-02-13 |
EP4248990A3 (en) | 2024-01-03 |
US11083790B2 (en) | 2021-08-10 |
LT3463457T (lt) | 2023-09-11 |
PL3463457T3 (pl) | 2023-08-21 |
JP2019517504A (ja) | 2019-06-24 |
FI3463457T3 (fi) | 2023-09-12 |
HRP20230864T1 (hr) | 2023-11-10 |
SI3463457T1 (sl) | 2023-09-29 |
PT3463457T (pt) | 2023-09-07 |
EP3463457B1 (en) | 2023-06-28 |
JP7175198B2 (ja) | 2022-11-18 |
HUE062398T2 (hu) | 2023-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT202300290T1 (it) | Blocco di pd-1 con nivolumab nel linfoma di hodgkin refrattario | |
IL269461B (en) | Cytidine-5-carboxamide modified nucleotide preparations and related methods | |
PL3177682T3 (pl) | Kompozycja utwardzalna i formowany wyrób zawierający kompozycję | |
GB201512640D0 (en) | Improvements in or relating to closures | |
GB201511915D0 (en) | Improvements in or relating to closures | |
HK1213275A1 (zh) | 具有抗衝擊性並具有改進的光學性質的 | |
ZA201606476B (en) | Genetic loci associated with increased fertility in maize | |
HK1251595A1 (zh) | 用於光學製品的組合物及用其製造的光學製品 | |
ZA201704866B (en) | Protective articles | |
SG11201610296YA (en) | Acrylic composition with olefin block copolymer | |
GB201409413D0 (en) | Polymer composition and heat -shrinkable article | |
ZA201703123B (en) | Combination long acting compositions and methods for hepatitis c | |
SG10201710894QA (en) | A polyethylene composition and process for polymerizing the same | |
EP2975181A4 (en) | SHOVEL FOR WORK VEHICLE AND WORKING VEHICLE WITH A SHOVEL | |
EP2985017A4 (en) | COMPOSITION COMPRISING A 1,2-ALKANE POLYOL | |
HUE045174T2 (hu) | Parenterális készítmények és alkalmazásuk | |
GB201617176D0 (en) | Improvements in or relating to closures | |
GB201615505D0 (en) | CR 2032/CR 2016/CR 2025/ All 3 volt batterys | |
GB201610289D0 (en) | Improvements in or relating to closures | |
GB201412638D0 (en) | Artist's implement | |
GB201309694D0 (en) | Artist's implement | |
GB201504973D0 (en) | Protective articles | |
GB201511421D0 (en) | Improvements in or relating to closures | |
GB201500543D0 (en) | The Edward's chronometer | |
GB201503447D0 (en) | Improvements in or relating to closures |